Public Employees Retirement Association of Colorado decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,203 shares of the life sciences company’s stock after selling 505 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Illumina were worth $10,015,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Ardevora Asset Management LLP lifted its position in Illumina by 14.2% during the first quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock valued at $31,446,000 after purchasing an additional 12,600 shares during the last quarter. Copper Rock Capital Partners LLC bought a new stake in shares of Illumina in the 2nd quarter worth approximately $10,888,000. Jupiter Wealth Management LLC bought a new stake in shares of Illumina in the 1st quarter worth approximately $387,000. Shell Asset Management Co. lifted its holdings in shares of Illumina by 5.8% in the 1st quarter. Shell Asset Management Co. now owns 24,863 shares of the life sciences company’s stock worth $7,725,000 after acquiring an additional 1,369 shares during the last quarter. Finally, Diversified Trust Co bought a new stake in shares of Illumina in the 1st quarter worth approximately $1,544,000. 90.95% of the stock is owned by institutional investors.
ILMN has been the subject of a number of recent research reports. Piper Jaffray Companies lowered their price objective on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a report on Tuesday, July 30th. Canaccord Genuity lowered shares of Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $330.00 to $300.00 in a report on Tuesday, July 30th. Deutsche Bank lowered their price objective on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a report on Friday, July 12th. ValuEngine upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Argus lowered their price objective on shares of Illumina to $340.00 and set a “buy” rating for the company in a report on Thursday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $330.92.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.03. The company had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm’s revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.43 EPS. As a group, analysts anticipate that Illumina, Inc. will post 6.04 EPS for the current year.
In other Illumina news, CEO Francis A. Desouza sold 3,000 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $301.25, for a total transaction of $903,750.00. Following the transaction, the chief executive officer now directly owns 64,200 shares of the company’s stock, valued at approximately $19,340,250. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $288.36, for a total transaction of $951,588.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,758 shares of company stock worth $17,479,206. Insiders own 0.38% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Growth and Income Funds
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.